SUPPLEMENTARY FINANCIAL INFORMATION (unaudited)

3 Months Ended

Mar. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

SUPPLEMENTARY FINANCIAL INFORMATION

SUPPLEMENTARY FINANCIAL INFORMATION(unaudited)

Selected financial information for the quarterly period noted is as follows:

(in thousands, except share and per share amounts)	Quarter Ended March 31, 2016
Revenue:
Impax Generic Product sales, gross	$	611,281
Less:
Chargebacks	217,354
Rebates	185,476
Product Returns	11,913
Other credits	29,354
Impax Generic Product sales, net	167,184
Rx Partner	2,835
Other Revenues	60
Impax Generic Division revenues, net	170,079
Impax Specialty Pharma sales, gross	82,073
Less:
Chargebacks	6,111
Rebates	2,853
Product Returns	1,508
Other credits	16,172
Impax Specialty Pharma sales, net	55,429
Other Revenues	—
Impax Specialty Pharma revenues, net	55,429
Total revenues	225,508
Gross profit	102,590
Net loss	$	(10,408	)
Net loss per common share:
Basic	$	(0.15	)
Diluted	$	(0.15	)
Weighted-average common shares outstanding:
Basic	70,665,394
Diluted	70,665,394

(in thousands, except share and per share amounts)	Quarter Ended March 31, 2015
Revenue:
Impax Generic Product sales, gross	$	355,321
Less:
Chargebacks	126,607
Rebates	83,130
Product Returns	6,427
Other credits	13,198
Impax Generic Product sales, net	125,959
Rx Partner	2,239
Other Revenues	543
Impax Generic Division revenues, net	128,741
Impax Specialty Pharma sales, gross	29,219
Less:
Chargebacks	5,561
Rebates	2,132
Product Returns	2,620
Other credits	4,778
Impax Specialty Pharma sales, net	14,128
Other Revenues	227
Impax Specialty Pharma revenues, net	14,355
Total revenues	143,096
Gross profit	59,234
Net loss	$	(6,333	)
Net loss per common share:
Basic	$	(0.09	)
Diluted	$	(0.09	)
Weighted-average common shares outstanding:
Basic	68,967,875
Diluted	68,967,875